About Petragen
Advancing precision medicine for pathological mineralization
Yale-founded. Science-driven. Built to deliver disease-modifying therapies where patients need them most.
Founded from world-leading ENPP1 research at Yale
Petragen was founded in 2021 out of the Braddock Laboratory at Yale University, where co-founder and Chief Scientific Officer Demetrios Braddock, MD, PhD has spent over two decades advancing the understanding of ENPP1 biology and its role in pathological mineralization. Dr. Braddock’s work on ENPP1 previously led to the creation of Inozyme Pharma, which went public on NASDAQ and was subsequently acquired by BioMarin Pharmaceutical. That same depth of scientific insight now drives Petragen’s therapeutic platform.
An integrated team with a proven track record
Petragen has assembled a team of experienced professionals spanning drug discovery, CMC and formulation, clinical development, regulatory affairs, periodontal clinical practice, and business development. With over 140 years of combined experience, the leadership team has collectively contributed to multiple NDA approvals, public offerings, and successful acquisitions. This is not a team learning on the job—it is a group of seasoned operators who have built and advanced therapeutic programs from concept through commercialization.
Focused where patient need is greatest
Rather than chasing crowded therapeutic areas like immunology and inflammation, neurology, or obesity, Petragen has chosen to focus on diseases where the unmet patient need far outweighs the latest M&A trends. Periodontal disease affects nearly 36 million people in the U.S. with virtually no disease-modifying therapeutics. Hypophosphatasia patients endure treatments costing up to $2 million per year with near daily injections. CPPD affects nearly 10 million people with no approved disease-modifying therapies. These are not niche academic exercises—they are real diseases with real patients who deserve better options.
Targeting disease where it happens
Petragen’s platform is built around the direct physical pathophysiology of mineralization-related diseases. Rather than targeting a distant node in a signaling pathway that may carry conflicting or competing biological effects, Petragen focuses on the mechanism at the point where disease actually occurs. This approach is designed to produce therapies that are precise, predictable, and genuinely disease-modifying across each of our indications.
Partner with Petragen
We welcome conversations with strategic investors, development partners, and scientific collaborators aligned with our mission.
Get in touch